T-Therapeutics Ltd
Qunwei Wang is an experienced scientist specializing in genomic recombineering and novel therapeutics discovery. Currently serving as the Group Lead for the Discovery pipeline at T-Therapeutics Ltd since January 2023, Qunwei previously held the position of Staff Scientist at the University of Cambridge from November 2018 to October 2023. Prior roles include Staff Scientist at the Wellcome Sanger Institute, Research Leader/Project Manager at Anhui Sinobioway Groups in China, Research Scientist at SCANCELL LIMITED, and Postdoctoral Research Fellow at the University of Nottingham. Academic achievements include a PhD in Oncology and a Master’s degree in Cancer Immunology from the University of Nottingham, as well as a Bachelor’s degree in Pharmacology from the University of Portsmouth.
T-Therapeutics Ltd
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.